and BMS has said it remains committed to developing it for IBD. It is hoping that a phase 2 trial in ulcerative colitis called IM011-127, which is using a higher dose of the drug and is due to ...
We'll review how everyday investors are using these tools to try to improve returns and mitigate risks. As artificial intelligence (AI) becomes more common and accessible, investors have begun ...
Disability was evaluated using the IBD-Disability Index (IBD-DI). Disease activity was measured using the Simple Clinical Colitis Activity Index (SCCAI) for UC and the Harvey-Bradshaw Index (HBI ...
Through use of precision medicine and machine learning (ML), the company’s cell-centred models will aid identification of patient subtypes and pair them with personalised IBD targets.